APVO - Aptevo gains nearly double after APVO436 + chemotherapy resulted in complete remission in AML

Aptevo Therapeutics (NASDAQ:APVO) soars 99.4% premarket after announcing a clinical update for its Phase 1b Expansion trial evaluating APVO436 in the treatment of acute myeloid leukemia (AML). A high-risk AML patient treated in Cohort 1 with a combination of chemotherapy plus APVO436 achieved a complete remission (CR) after one cycle of therapy. The patient tolerated treatment without evidence of overt toxicity. The overarching goal of the Phase 1b expansion phase study is to determine if APVO436 treatments can improve the quality of remission in high-risk AML patients by reducing the residual chemotherapy-resistant measurable residual disease (MRD) burden. Aptevo believes that APVO436 has the potential to help achieve complete remissions without MRD and thereby reduce their risk of leukemic relapses. The company also believes that the use of APVO436 for targeting MRD in AML may be associated with a very low risk of cytokine release syndrome as well as an increased likelihood of

For further details see:

Aptevo gains nearly double after APVO436 + chemotherapy resulted in complete remission in AML